Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
Antidepressants that inhibit neuronal norepinephrine reuptake are not associated with increased spontaneous reporting of cardiomyopathy
Journal of Psychopharmacology, 04/02/09
Ratcliffe S et al. - There is no direct relationship between antidepressants with greater norepinephrine reuptake inhibitor activity (affinity for norepinephrine reuptake transporter or selectivity for norepinephrine versus serotonin) and reporting of cardiomyopathy.
Methods- Using a data mining algorithm (DMA), this study quantitatively investigated the association between antidepressant agents that predominantly exert their effects through inhibiting neuronal norepinephrine reuptake (rather than serotonin) and cardiomyopathy.
- This study retrospectively applied a Bayesian DMA, the Bayesian Confidence Propagation Neural Network, to the cumulative reports in the Food and Drug Administration Adverse Event Reporting System (through the fourth quarter of 2006) and World Health Organization Vigibase (through the second quarter of 2007) databases.
- A threshold of the posterior interval 95% lower limit > 0 was used to define a signal of disproportionate reporting with individual or groups of antidepressants and cardiomyopathy-related terms.
- The analysis suggested that there is no direct relationship between antidepressants with greater norepinephrine reuptake inhibitor activity (affinity for norepinephrine reuptake transporter or selectivity for norepinephrine versus serotonin) and reporting of cardiomyopathy.
- In contrast, an inverse correlation might exist with a higher number of cases identified with tricyclic antidepressants showing lower norepinephrine reuptake inhibition and the serotonin/norepinephrine reuptake inhibitors as well as with serotonin/norepinephrine/slight dopamine reuptake inhibitor.
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Homocysteine lowering interventions for preventing cardiovascular events
Cochrane Reviews, 10/19/09
Omega-3 fatty acids and heart failure
Current Atherosclerosis Reports, 11/12/09
Vitamin D and cardiovascular disease
Current Atherosclerosis Reports, 11/12/09
Today in Internal Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
Homocysteine lowering interventions for preventing cardiovascular events
Cochrane Reviews, 10/19/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Today in Psychiatry...keeping you current
Receive free subspecialty "5-minute updates" via email
An algorithm for the pharmacological treatment of depression
Acta Psychiatrica Scandinavica, 11/04/09
Is Monotherapy as Good as Polypharmacy in Long-Term Treatment of Bipolar Disorder
Canadian Journal of Psychiatry, 11/16/09
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Sponsor
Article Search
Sponsor


See Latest Articles


